Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, 3000, Belgium
NCT Number: NCT01002651
The investigational study product used in this clinical trial is a soft drink containing an arabinoxylan-oligosaccharides (AXOS) preparation extracted from wheat bran (hereafter called Wheat Bran Extract, WBE).
The objective of this study is to analyze the effect of the intake of two WBE doses on various parameters of gastrointestinal health. Additionally, safety was analyzed using treatment emergent Adverse Events (AEs) and clinical blood parameters.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Leuven, 3000, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
Other names: arabinoxylan-oligosaccharides (AXOS)
soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
Time frame: day 19 or 20 of each intervention
Time frame: day 19 or 20 of each intervention
Time frame: day 19-21 of each intervention
Time frame: third week of each intervention
Time frame: whole study
Time frame: day 21 of each intervention
Fugeia NV
Industry
In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details